<- Go Home
Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Market Cap
$33.4M
Volume
11.5M
Cash and Equivalents
$7.3M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.91
52 Week Low
$0.11
Dividend
N/A
Price / Book Value
3.37
Price / Earnings
-1.56
Price / Tangible Book Value
4.38
Enterprise Value
$26.1M
Enterprise Value / EBITDA
N/A
Operating Income
-$7.2M
Return on Equity
198.28%
Return on Assets
-71.63
Cash and Short Term Investments
$7.3M
Debt
N/A
Equity
$9.9M
Revenue
N/A
Unlevered FCF
-$3.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium